程序性细胞死亡受体1配体及可溶性程序性细胞死亡受体1配体对肝细胞癌预后的预测价值与争议

Value of programmed cell death ligand 1 and soluble programmed cell death ligand 1 in predicting the prognosis of hepatocellular carcinoma and related controversies

目前针对肝细胞癌(以下简称肝癌)的治疗手段多样,包括手术治疗、介入治疗、免疫治疗等,尽管如此,肝癌患者的5年生存率也仅为12.5%。影响肝癌预后的因素一直以来都是研究的焦点。近几年,随着程序性细胞死亡受体1(PD-1)抑制剂在治疗肝癌方面的研究逐渐深入,作为其配体的PD-L1及可溶性PD-L1(sPD-L1)在肝癌免疫逃逸中的作用及预后预测价值也开始得到广泛关注与研究。重点阐述了现阶段PD-L1和sPD-L1作为免疫标志物在评价肝癌预后中的争议、共识及进展。

At present,there are various treatment methods for hepatocellular carcinoma(HCC),including surgical treatment,interventional treatment,and immunotherapy,and even so,the five-year survival rate of HCC patients is only 12.5%.Influencing factors for the prognosis of HCC have always been the focus of research.With the in-depth research on programmed cell death protein 1(PD-1)inhibitors in the treatment of HCC in recent years,the role of programmed cell death ligand 1(PD-L1)and soluble programmed cell death ligand 1(sPD-L1),as the ligands of PD-1,in immune escape and their value in predicting prognosis have attracted more and more attention.This article elaborates on the current controversies,consensus,and advances in PD-L1 and sPD-L1 as immune markers in evaluating the prognosis of HCC.